title: The MOTIVATE trials: maraviroc therapy in antiretroviral treatment-experienced HIV-1-infected patients.
abstract: Although the use of combination antiretroviral therapy has resulted in spectacular improvements in morbidity and mortality of HIV-1 infected patients, a need for the development of antiretroviral compounds with new mechanisms of action remains. Maraviroc (Celsentri(®); ViiV Healthcare, Middlesex, UK) is the only drug of the class of chemokine (C-C motif) receptor 5 antagonists registered for treatment for HIV-1-infected antiretroviral therapy-experienced patients. Registration was based on the MOTIVATE-1 and -2 studies, which compared the efficacy and tolerability of maraviroc in combination with optimized background therapy with placebo. The aim of this paper is to review the MOTIVATE studies and to discuss issues related to maraviroc therapy in clinical practice such as assessment of HIV-1 coreceptor tropism.
authors.affiliation: Department of Internal Medicine and Infectious Diseases, University Medical Center Utrecht, Huispostnummer F.02.126, Postbus 85500, 3508 GA Utrecht, The Netherlands. s.f.l.vanlelyveld@umcutrecht.nl
authors.forename: Steven F L
authors.initials: SF
authors.lastname: van Lelyveld
authors.forename: Annemarie M J
authors.initials: AM
authors.lastname: Wensing
authors.forename: Andy I M
authors.initials: AI
authors.lastname: Hoepelman
mesh_terms: D044966:Anti-Retroviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000502:physiology; D006801:Humans; D000077592:Maraviroc; D016032:Randomized Controlled Trials as Topic; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use*; D056189:Viral Tropism
chemical_list: D044966:Anti-Retroviral Agents; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D014230:Triazoles; D000077592:Maraviroc